Cytori Therapeutics, Inc. (CYTX) Reports In-Line Q3 Loss of 15c/Share

Cytori Therapeutics, Inc. (NASDAQ: CYTX) reported Q3 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.58 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance